Statement Of Cash Flows [Abstract]

Mithra Pharmaceuticals S.A. - Filing #3183075

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	59 620 EUR	59 620 EUR	—	116 875 EUR	116 875 EUR	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories	—	6 873 EUR	—	—	8 470 EUR	—	—
Adjustments for share-based payments	—	1 983 EUR	—	—	1 065 EUR	—	—
Cash flows from (used in) operating activities	—	56 819 EUR	—	—	76 788 EUR	—	—
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	—	169,000 EUR	—	—	- EUR	—	—
Purchase of property, plant and equipment, classified as investing activities	—	6 356 EUR	—	—	11 483 EUR	—	—
Purchase of intangible assets, classified as investing activities	—	19 302 EUR	—	—	9 699 EUR	—	—
Cash flows from (used in) investing activities	—	25 490 EUR	—	—	54 682 EUR	—	—
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities	—	6 663 EUR	—	—	7 193 EUR	—	—
Proceeds from government grants, classified as financing activities	—	154,000 EUR	—	—	41,000 EUR	—	—
Interest paid, classified as financing activities	—	9 862 EUR	—	—	9 364 EUR	—	—
Cash flows from (used in) financing activities	—	77 869 EUR	—	—	25 646 EUR	—	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	147,000 EUR	—	—	21,000 EUR	—	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	4 440 EUR	—	—	105 824 EUR	—	—
Cash and cash equivalents	28,285,000 EUR	—	—	32,872,000 EUR	—	—	138,675,000 EUR